Metabolic Solutions Development
Michigan-based Metabolic Solutions develops insulin sensitizers for diabetes, liver, kidney, and neurodegenerative diseases.
Founded
2011Michigan-based Metabolic Solutions develops insulin sensitizers for diabetes, liver, kidney, and neurodegenerative diseases.
Metabolic Solutions Development Company (MSDC), based in Kalamazoo, Michigan, was founded with the mission to develop innovative therapeutics targeting metabolic diseases linked to age-related mitochondrial dysfunction. The company focuses on creating insulin sensitizers aimed at treating conditions such as type 2 diabetes, non-alcoholic fatty liver disease (NASH), polycystic kidney disease, and neurodegenerative diseases. Their core vision is to offer new hope for the prevention and treatment of these chronic conditions, serving patients across the United States.
Notable affiliated individuals include the executive team at Cirius Therapeutics, which completed a significant Series A financing round to fund a Phase 2b study of MSDC-0602K in NASH. This funding marks a key achievement for MSDC, enabling further development of their promising drug candidates. The company's impact lies in its potential to revolutionize treatment paradigms for metabolic diseases, addressing a critical need for effective therapies in these areas.
Companies similar to Metabolic Solutions Development include Cirius Therapeutics, Restor Metabolix, KinDex Pharmaceuticals and MetaModix.
Metabolic Solutions Development was founded in 2011.
Metabolic Solutions Development's headquarters is located in Kalamazoo, MI, US.
Metabolic Solutions Development's most recent funding round was for $16.1M (USD) in September 2015.
As of Sep 25, 2015, Metabolic Solutions Development has disclosed funding of $58.5M (USD). Undisclosed round amounts are excluded.
Metabolic Solutions Development has 14 employees as of Feb 5, 2024.
MetaModix
